Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20437153 | 0.94 | MEN1 (0.42) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL21626590 | 0.93 | MEN1 (0.36) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL21626600 | 0.91 | MEN1 (0.35) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL21626599 | 0.91 | MEN1 (0.35) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL20437165 | 0.89 | HDAC8 (0.42) | MEN1POLBKMT2AMETBCL2 | |
| SCHEMBL20437159 | 0.89 | HDAC8 (0.42) | MEN1POLBKMT2AMETBCL2 | |
| SCHEMBL20437152 | 0.89 | BCL2 (0.40) | MEN1POLBKMT2AALOX5BCL2 | |
| SCHEMBL20437150 | 0.89 | BCL2 (0.40) | MEN1POLBKMT2AALOX5BCL2 | |
| SCHEMBL20806017 | 0.89 | MET (0.35) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL21626648 | 0.88 | MEN1 (0.43) | MEN1POLBKMT2AALOX5MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| EP-3573987-B1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-03-10 | — | — | EP | disclosed |
| WO-2020016129-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-01-23 | — | — | WO | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| WO-2018138293-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885 |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.